In order for organ-specific autoimmune diseases to develop, at least two conditions have to be met. First, there has to be a deficit in the central and/or peripheral immune tolerance, that is, in the elimination and regulation of autoreactive lymphocytes. Second, lymphocytes have to infiltrate the target organ and become re-activated in situ. This second step requires interaction with tissue resident cells, which themselves can mount inflammatory responses that enhance the autoimmune process. In multiple sclerosis (MS), the key cells in the crosstalk between the peripheral immune cells and the central nervous system (CNS) during lesion formation are astrocytes. Accumulation of lymphocytes and monocytes, the effector cells for inflammatory demyelination, is not a passive process but requires active recruitment across multiple barriers into the CNS. Astrocytes are uniquely positioned to facilitate (or prevent) their recruitment, as they regulate blood-brain barrier (BBB) permeability, form a secondary barrier directly adjacent to the CNS parenchyma (glia limitans), and, in an activated state, are a principal source of chemoattractants. 1 Although we are focusing here on astroglial functions relevant to early lesion formation, astrocytes also contribute to later stages of lesion development, for example, by limiting inflammation through scar formation and by promoting remyelination.
What is the evidence that astrocytes drive MS lesion formation?
In acute MS lesions, astrocytes located at the leading edges of demyelination have a highly reactive morphology and express multiple pro-inflammatory mediators, including vasoactive molecules, chemoattractants, adhesion molecules, and cytokines, which increase BBB permeability and promote lymphocyte recruitment, activation, and survival. 2 Astrocyte activation occurs early during lesion development before significant numbers of inflammatory cells enter the CNS 3 . This timing suggests that reactive astrocytes in fact facilitate the large-scale influx of leukocytes. This has been confirmed in a murine model of MS, experimental autoimmune encephalomyelitis, where astrocytespecific genetic deletion of several immune mediators resulted in reduced neuroinflammation and disease severity. Moreover, astrocytes can adopt a neurotoxic phenotype, termed "A1" analogous to the "M1" phenotype of macrophages, which is abundant in active MS lesions and induces death in oligodendrocytes and neurons through a yet-to-beidentified neurotoxin. 4 Thus, reactive astrocytes provide a multitude of local innate immune responses that both critically engage infiltrating immune cells and cause direct neurotoxicity. These responses might tip the scale from a transient, nonpathological lymphocyte infiltrate to the development of a demyelinating MS lesion.
Target tissue responses in other autoimmune diseases
Further evidence for the critical role of astrocytes in MS lesion formation can be inferred from the inflammatory responses of target tissue in other autoimmune diseases. 5 The concept that resident cells within the target organ regulate the inflammatory process and become complicit in (or limit) self-reactive immune responses is more established in other autoimmune disorders such as rheumatoid arthritis (RA). Activated synovial fibroblasts in RA produce inflammatory chemokines and B-cell-activating factor that promote and maintain inflammation in the synovium. Moreover, synovial fibroblasts secrete toxic cytokines, proliferate and infiltrate joint tissue, and thus become active drivers of joint destruction. Accordingly, the next generation of RA therapies is aimed at fibroblasts and their detrimental role in perpetuating inflammation. 6 Similarly, autoimmune inflammation in Sjögren's disease, Celiac disease, autoimmune hepatitis, and type 1 diabetes is associated with expression of pro-inflammatory molecules and/or loss of co-inhibitory molecules such as chemokines, NKG2D ligands, and programmed death-ligand 1 (PD-L1) in target tissue cells. Hepatic stellate cells, which share many similarities with astrocytes, including the expression of glial fibrillary acidic protein (GFAP), acquire a highly reactive and proliferative phenotype in autoimmune hepatitis and are major contributors to hepatic fibrosis. 7 Thus, participation in the autoimmune process is not unique to astrocytes, but a general feature of target tissue cells with innate immune capabilities. Consequently, the predisposition of the target tissue to promote local inflammation may in part determine an individual's susceptibility to organspecific autoimmunity.
Why have astrocytes received little attention in MS?
The role of astrocytes in lesion formation is perhaps obscured by the resounding success of modern MS therapies such as natalizumab (Tysabri™), ocrelizumab (Ocrevus™), and alemtuzumab (Lemtrada™), all of which target peripheral immune cells. It is tempting to interpret the efficacy of these treatments in suppressing lesion formation as evidence that lymphocytes are the only cells relevant to lesion formation, when in fact it only means that lymphocytes are necessary for inflammatory demyelination. However, MS treatments such as fingolimod (Gilenya™) target both peripheral immune cells and CNS cells. Although it is unclear which cellular target is more important in MS, the principal mechanism through which fingolimod reduces inflammation and disease severity in murine autoimmune encephalomyelitis is the modulation of astrocyte function. 8 Another potential reason for underestimating their role in MS lesion pathogenesis is that far less is known about astrocytes than, for example, lymphocytes, because astrocytes are difficult to isolate from adult human brain. As a case in point, the genetic variants associated with MS susceptibility have been suggested to interfere predominantly with lymphocyte function. However, since the genomic and epigenomic datasets on which these analyses rely are not available for astrocytes and other CNS cells, the impact of risk variants on these cell types is simply unknown. In this context, we have recently shown that a specific risk variant for MS, rs7665090G, is associated with profound dysregulation of astrocyte function, which causes increased astrocyte-mediated lymphocyte recruitment to MS lesions. 9 Given these results and the many mechanisms through which astrocytes participate in MS lesion formation, it is likely that additional risk variants affect astrocyte responses and thereby confer MS susceptibility through astrocyte-mediated mechanisms.
Summary and outlook
Astrocytes have been traditionally viewed as bystander cells in MS lesion development, whose main role is to form glial scars once the inflammation has subsided. This view has changed dramatically. Astrocytes have now emerged as critical contributors to MS lesion formation, through their control of CNS access for peripheral immune cells, their ability to mount persistent pro-inflammatory responses, and even through neurotoxic effects. In this regard, astrocytes might be similar to certain target tissue cells in other autoimmune diseases, which also enable and exacerbate local inflammation. This theme underscores that autoimmune diseases are the result of dysregulation not only of peripheral immune processes but also of inflammatory responses from the target organ to the developing assault.
Great strides are currently being made in identifying astrocyte-specific pathways that modulate CNS inflammation, such as the aryl hydrocarbon receptor signaling in astrocytes, which is regulated by environmental factors including dietary tryptophan. 10 In addition, new techniques such as single nuclear RNA sequencing are being employed to dissect astrocyte heterogeneity in healthy and MS brain. Finally, the systematic correlation of MS risk variants with epigenetic chromatin landscapes and RNA expression profiles of astrocytes will help determine the genetic variants that drive MS susceptibility by dysregulating astrocyte function. All this knowledge will be useful in identifying novel therapeutic targets for manipulating astrocyte responses, particularly in progressive MS where existing drugs offer no or minimal benefit.
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Astrocytes play a crucial role in the formation and evolution of MS lesions -No Nicole Kerlero de Rosbo
To debate whether or not astrocytes can play a crucial role in the formation and evolution of multiple sclerosis (MS) lesions, one must first acknowledge the evolution of our understanding of astrocytes from mere support cells for neurons to crucial players in the maintenance of central nervous system (CNS) homeostasis under non-diseased conditions. Their multiple physiologic functions include not only structural and metabolic support to neurons and axons, but also, among others, regulation of local blood flow and solute waste clearance from the interstitial glymphatic channels. 1 Of utmost importance in the context of MS is the crucial role of astrocytes in the maintenance of the blood-brain barrier (BBB). If we consider that astrocytes are essential in ensuring BBB integrity, then, yes, we can say that they play a crucial role, albeit indirect, in the formation of MS lesions, as BBB damage is critical in the ensuing damage. However, not all diseases in which BBB disruption occurs-and indeed, this seems to be the case for most, if not all, neurological diseases to a greater or lesser extent 2 -are associated with demyelinating lesions, which are the hallmark of MS. Conversely, demyelination is not a characteristic of neurodegenerative diseases such as amyotrophic lateral sclerosis, where activated astrocytes are determinant of disease progression. 3 Instead, a number of features argue for the infiltrating inflammatory immune cells being the main driver of lesion formation in MS:
cates that the pathogenic process involved in the onset of MS plaques is perivascular, evolving from inflammatory immune cell infiltration from the periphery through a leaking BBB. In actively induced experimental autoimmune encephalomyelitis (EAE), the model for MS, perivascular inflammatory infiltration leading to demyelination is massive, and adoptive transfer of activated myelin-specific T cells is sufficient to induce disease in naïve mice; most importantly, activated T cells that do not recognize a brain antigen, and thereby do not home to the CNS, are incapable of inducing disease. Perivascular infiltration of myelin-specific T cells leads to the recruitment of monocytes and a recent study suggested that recruitment of peripheral macrophages, which are mostly responsible for myelin destruction in active lesions, could be related to the deposition of fibrinogen, a central blood coagulation protein, into the CNS after moderate damage of the BBB by the perivascular T-cell infiltrates. 4 In addition to activation of antigen-presenting cells, including dendritic cells, and ensuing T-cell recruitment to the CNS, fibrinogen has also been implicated in the activation of microglia, and in EAE, the initiation of neuroinflammation is strongly associated with the attraction of pathogenic T cells toward perivascular
